Ascletis Pharma Inc. (HKG:1672)

Ascletis Pharma Statistics

Total Valuation

Ascletis Pharma has a market cap or net worth of HKD 16.44 billion. The enterprise value is 14.32 billion.

Market Cap	16.44B
Enterprise Value	14.32B

Important Dates

The next estimated earnings date is Friday, August 14, 2026.

Earnings Date	Aug 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Ascletis Pharma has 1.06 billion shares outstanding. The number of shares has decreased by -2.90% in one year.

Current Share Class	1.06B
Shares Outstanding	1.06B
Shares Change (YoY)	-2.90%
Shares Change (QoQ)	+2.08%
Owned by Insiders (%)	51.61%
Owned by Institutions (%)	4.06%
Float	233.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	30.80
PS Ratio	7,283.35
PB Ratio	7.64
P/TBV Ratio	7.68
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-35.77
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.05, with a Debt / Equity ratio of 0.00.

Current Ratio	15.05
Quick Ratio	15.00
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,954.46

Financial Efficiency

Return on equity (ROE) is -18.45% and return on invested capital (ROIC) is -15.48%.

Return on Equity (ROE)	-18.45%
Return on Assets (ROA)	-14.45%
Return on Invested Capital (ROIC)	-15.48%
Return on Capital Employed (ROCE)	-24.99%
Weighted Average Cost of Capital (WACC)	6.86%
Revenue Per Employee	11,172
Profits Per Employee	-1.98M
Employee Count	202
Asset Turnover	0.00
Inventory Turnover	0.48

Taxes

In the past 12 months, Ascletis Pharma has paid 563,082 in taxes.

Income Tax	563,082
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +182.66% in the last 52 weeks. The beta is 0.47, so Ascletis Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.47
52-Week Price Change	+182.66%
50-Day Moving Average	16.45
200-Day Moving Average	13.71
Relative Strength Index (RSI)	36.90
Average Volume (20 Days)	1,861,898

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ascletis Pharma had revenue of HKD 2.26 million and -400.48 million in losses. Loss per share was -0.41.

Revenue	2.26M
Gross Profit	586,451
Operating Income	-539.19M
Pretax Income	-399.92M
Net Income	-400.48M
EBITDA	-524.85M
EBIT	-539.19M
Loss Per Share	-0.41

Balance Sheet

The company has 2.12 billion in cash and 5.74 million in debt, with a net cash position of 2.11 billion or 1.99 per share.

Cash & Cash Equivalents	2.12B
Total Debt	5.74M
Net Cash	2.11B
Net Cash Per Share	1.99
Equity (Book Value)	2.15B
Book Value Per Share	2.17
Working Capital	2.00B

Cash Flow

Operating Cash Flow	-463.79M
Capital Expenditures	n/a
Depreciation & Amortization	14.81M
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	25.99%
Operating Margin	-23,892.11%
Pretax Margin	-17,720.61%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Ascletis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.90%
Shareholder Yield	2.90%
Earnings Yield	-2.44%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1